Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 25 Hydroxycholecalciferol
2. 25 Hydroxycholecalciferol Monohydrate
3. 25 Hydroxyvitamin D 3
4. 25 Hydroxyvitamin D3
5. 25-hydroxycholecalciferol
6. 25-hydroxycholecalciferol Monohydrate
7. 25-hydroxyvitamin D 3
8. 25-hydroxyvitamin D3
9. Anhydrous, Calcifediol
10. Calcidiol
11. Calcifediol Anhydrous
12. Calcifediol, (3 Alpha,5z,7e)-isomer
13. Calcifediol, (3 Beta,5e,7e)-isomer
14. Calderol
15. Dedrogyl
16. Hidroferol
17. Monohydrate, 25-hydroxycholecalciferol
1. Calcidiol
2. 25-hydroxyvitamin D3
3. 19356-17-3
4. 25-hydroxycholecalciferol
5. Calcifediol Anhydrous
6. Hidroferol
7. 25-hydroxyvitamin D
8. Calderol
9. Didrogyl
10. Calcifediolum
11. Rayaldee
12. Ro 8-8892
13. 5,6-cis-25-hydroxyvitamin D3
14. Calcifediol [inn]
15. Cholecalciferol, 25-hydroxy-
16. Chebi:17933
17. (3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol
18. T0wxw8f54e
19. 3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol
20. Ncgc00161326-04
21. Calcifidiol
22. Delakmin
23. 25-hydroxy Vitamin D3
24. (3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
25. (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
26. U-32070e
27. U 32070 E
28. 25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / Calcidiol
29. 25-hydroxycholescalciferol
30. Calcifediolum [inn-latin]
31. Rovimix Hy-d
32. (1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol
33. (3b,5z,7e)- 9,10-secocholesta-5,7,10(19)-triene-3,25-diol
34. Vitamin D, 25-hydroxy-
35. Hy-d
36. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
37. 36149-00-5
38. 25-(oh)vitamin D3
39. 5,6-trans-25-hydroxycholescalciferol
40. Unii-t0wxw8f54e
41. Ryaldee
42. Bml2-e02
43. (5z,7e)-(3s)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
44. 25(oh)d3
45. Einecs 242-990-9
46. Mfcd00867077
47. U 32070e
48. Calcifediol [mi]
49. (5z,7e)-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
50. 5,6-trans-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol
51. Spectrum5_001931
52. Dsstox_cid_2721
53. 25-hydroxy-cholecalciferol
54. Calcifediol,anhydrous
55. Schembl3296
56. Chembl1040
57. Dsstox_rid_76699
58. Dsstox_gsid_22721
59. Bspbio_001411
60. Calcifediol, Anhydrous
61. (3s,5z,7e)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
62. Gtpl6921
63. Dtxsid0022721
64. Chebi:94743
65. Amy2863
66. Bcpp000306
67. Dm100
68. Hms1361g13
69. Hms1791g13
70. Hms1989g13
71. Hms2089l21
72. Hms3402g13
73. 64719-49-9
74. Act06833
75. Zinc4474414
76. Tox21_111987
77. (3s,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
78. 9,10-secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5z,7e)-
79. Bdbm50521013
80. Calcifediol,anhydrous [vandf]
81. Lmst03020246
82. S1469
83. Akos015965097
84. Bcp9000472
85. Ccg-268657
86. Cs-0800
87. Db00146
88. Idi1_033881
89. Ncgc00161326-01
90. Ac-31367
91. Hy-32351
92. Cas-19356-17-3
93. 25-hydroxycholecalciferol, >=98% (hplc)
94. C01561
95. Ab01275461-01
96. Ab01275461_02
97. 356c173
98. A923587
99. Q139307
100. Sr-05000001468
101. Sr-05000001468-1
102. W-201718
103. 25-hydroxyvitamin D3 Monohydrate, >=99.0% (hplc)
104. 9,10-secocholesta-5,7,10(19)-triene-3b,25-diol
105. Brd-k77175907-001-01-5
106. B91135ec-8937-4d8b-a533-ccd82f33c1b0
107. Calcifediol, European Pharmacopoeia (ep) Reference Standard
108. (5e,7e)-9,10-secocholesta-5,7,10(19)-triene-3beta,25-diol
109. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, 98% (cp)
110. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, 98% (cp)
111. 25-hydroxyvitamin D3 Solution, 50 Mug/ml In Ethanol, 98% (cp)
112. Calcifediol, United States Pharmacopeia (usp) Reference Standard
113. (3s,5z,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-3,25-diol
114. (5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3b,25-diol Monohydrate
115. 9,10-secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5z,7e)-
116. (?r,1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1h-indene-1-pentanol
117. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol
118. (s,z)-3-((e)-2-((1r,3as,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol
119. 1h-indene-1-pentanol, Octahydro-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.r,1r,3as,4e,7ar)-
120. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material
121. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 400.6 g/mol |
|---|---|
| Molecular Formula | C27H44O2 |
| XLogP3 | 6.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 6 |
| Exact Mass | 400.334130642 g/mol |
| Monoisotopic Mass | 400.334130642 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 655 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
Treatment of secondary hyperparathyroidism (SHPT)
Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)
A - Alimentary tract and metabolism
A11 - Vitamins
A11C - Vitamin a and d, incl. combinations of the two
A11CC - Vitamin d and analogues
A11CC06 - Calcifediol
H - Systemic hormonal preparations, excl. sex hormones and insulins
H05 - Calcium homeostasis
H05B - Anti-parathyroid agents
H05BX - Other anti-parathyroid agents
H05BX05 - Calcifediol
Absorption
Readily absorbed.
Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.
288 hours
Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
As part of the expanded collaboration, Calcifediol will target the Vitamin D receptor to address secondary hyperparathyroidism.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Nicoya Therapeutics (Shanghai) Co., Ltd.
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration April 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Nicoya Therapeutics (Shanghai) Co., Ltd.
Deal Size : $115.0 million
Deal Type : Expanded Collaboration
Opko Health Expands Nicoya Agreement for RAYALDEE® in Greater China
Details : As part of the expanded collaboration, Calcifediol will target the Vitamin D receptor to address secondary hyperparathyroidism.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
April 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
CTAP101 (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Nephrology Brand Name: CTAP101
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CTAP101 (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : CTAP101
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 27, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: VFMCRP
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : VFMCRP
Deal Size : Inapplicable
Deal Type : Inapplicable
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact iPTH.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact ...
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a 2-week follow-up.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a...
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 30, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Rayaldee
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: CSL Vifor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : CSL Vifor
Deal Size : Undisclosed
Deal Type : Termination
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
Details : OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
May 24, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rayaldee (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Details : Rayaldee (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 16, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients
Details : The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 15, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.
Lead Product(s): Calcifediol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee
Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Calcifediol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients
Details : The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 01, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Filibon
Dosage Form : CAP
Dosage Strength : 400u
Packaging : 30X1u
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Vitafediol
Dosage Form : Soft Capsule
Dosage Strength : 0.266mg
Packaging :
Approval Date : 17/07/2024
Application Number : 69012
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : DIDROGYL
Dosage Form : Oral Drops Solution
Dosage Strength : 1.5 mg/10 ml
Packaging : 10 ML 0.15 MG/ML - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Rayaldee ?g
Dosage Form : Extended Release Capsule
Dosage Strength : 30mcg
Packaging :
Approval Date : 22/12/2020
Application Number : 67614
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : RAYALDEE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 0.03MG
Packaging :
Approval Date : 2016-06-17
Application Number : 208010
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Hidroferol
Dosage Form : Soft Capsule
Dosage Strength :
Packaging :
Approval Date : 30-11-2023
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : VIDENKA
Dosage Form : Oral Drops Solution
Dosage Strength : 0.15 mg/ml
Packaging : 10 ML 0.15 MG/ML - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CALDEROL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 0.02MG
Packaging :
Approval Date : 1982-01-01
Application Number : 18312
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CALDEROL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 0.05MG
Packaging :
Approval Date : 1982-01-01
Application Number : 18312
Regulatory Info : DISCN
Registration Country : USA

Regulatory Info :
Registration Country : Italy
Brand Name : Didrogyl
Dosage Form : Calcifediolo 1,5Mg/10Ml Oral Use
Dosage Strength : os gtt soluz 1.5 mg 10 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : RAYALDEE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 0.03MG
Approval Date : 2016-06-17
Application Number : 208010
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CALDEROL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 0.02MG
Approval Date : 1982-01-01
Application Number : 18312
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CALDEROL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 0.05MG
Approval Date : 1982-01-01
Application Number : 18312
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Dosage Form : Emulsion, Tablet
Grade : Oral, Ophthalmic
Category : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Grade : Not Available
Category : Coating Systems & Additives, Film Formers & Plasticizers
Dosage Form : Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Coating Systems & Additives
Application : Chewable & Orodispersible Aids, Coating Systems & Additives
Excipient Details : Instacoat CFC is an HPMC & xylitol-based high-speed optimized chewable and crunchy film coating material.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Grade : Not Available
Category : Coating Systems & Additives, Film Formers & Plasticizers
Grade : Not Available
Category : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Application : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Excipient Details : Controlled Release, Direct Compression,Wet Granulation,Tablet Coating, Liquid Solutions and Suspensions
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Fillers, Diluents & Binders, Granulation
Dosage Form : Tablet
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Enteric Coatings
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Immediate Release
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
87
PharmaCompass offers a list of Calcifediol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Calcifediol manufacturer or Calcifediol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcifediol manufacturer or Calcifediol supplier.
A Didrogyl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Didrogyl, including repackagers and relabelers. The FDA regulates Didrogyl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Didrogyl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Didrogyl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Didrogyl supplier is an individual or a company that provides Didrogyl active pharmaceutical ingredient (API) or Didrogyl finished formulations upon request. The Didrogyl suppliers may include Didrogyl API manufacturers, exporters, distributors and traders.
click here to find a list of Didrogyl suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Didrogyl DMF (Drug Master File) is a document detailing the whole manufacturing process of Didrogyl active pharmaceutical ingredient (API) in detail. Different forms of Didrogyl DMFs exist exist since differing nations have different regulations, such as Didrogyl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Didrogyl DMF submitted to regulatory agencies in the US is known as a USDMF. Didrogyl USDMF includes data on Didrogyl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Didrogyl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Didrogyl suppliers with USDMF on PharmaCompass.
A Didrogyl CEP of the European Pharmacopoeia monograph is often referred to as a Didrogyl Certificate of Suitability (COS). The purpose of a Didrogyl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Didrogyl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Didrogyl to their clients by showing that a Didrogyl CEP has been issued for it. The manufacturer submits a Didrogyl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Didrogyl CEP holder for the record. Additionally, the data presented in the Didrogyl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Didrogyl DMF.
A Didrogyl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Didrogyl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Didrogyl suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Didrogyl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Didrogyl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Didrogyl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Didrogyl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Didrogyl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Didrogyl suppliers with NDC on PharmaCompass.
Didrogyl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Didrogyl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Didrogyl GMP manufacturer or Didrogyl GMP API supplier for your needs.
A Didrogyl CoA (Certificate of Analysis) is a formal document that attests to Didrogyl's compliance with Didrogyl specifications and serves as a tool for batch-level quality control.
Didrogyl CoA mostly includes findings from lab analyses of a specific batch. For each Didrogyl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Didrogyl may be tested according to a variety of international standards, such as European Pharmacopoeia (Didrogyl EP), Didrogyl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Didrogyl USP).